HIV and ARV Therapy Accelerate Bone Loss Bone loss is common among people living with HIV before they begin antiretroviral (ARV) therapy, and it worsens upon starting treatment, especially if the regimen contains Combivir, according to a new report published in the July 17 issue of AIDS.
June 29, 2009
High Percentage of U.S. Residents Receiving Late HIV Diagnoses
Forty-five percent of people newly diagnosed with HIV infection in the United States progress to AIDS within three years, according to new data published by the U.S. Centers for Disease Control and Prevention in the June 26 issue of Morbidity and Mortality Weekly Report. The findings suggest that many people are being diagnosed late in the course of their HIV infection; the findings also underscore, according to the CDC authors, the need for expanded testing efforts in order to link people to necessary care as soon as possible.
June 26, 2009
Improving Survival From Non-Hodgkin’s Lymphoma Survival among people with HIV who are diagnosed with non-Hodgkin’s lymphoma (NHL) continues to improve, according to an encouraging reported published online June 15 in AIDS. The study found two thirds of people diagnosed with the cancer survived at least one year after diagnosis.
June 24, 2009
Second-Line Treatment for PCP a Viable Alternative Neutrexin (trimetrexate) combined with Leucovorin (folinic acid) is an effective and safe treatment option for people who don’t respond to their first treatment regimen for Pneumocystis pneumonia (PCP), according to a study published in the June 19 issue of AIDS.
June 23, 2009
HIV Infection and Diabetes Risk
HIV-positive people may face a lower risk of diabetes than their HIV-negative peers, according to new data comparing HIV-positive and HIV-negative veterans and published in the June 19 issue of AIDS. However, the risk may be higher among those with certain risk factors, including hepatitis C virus (HCV) coinfection, obesity and the long-term use of certain antiretroviral (ARV) medications.
June 22, 2009
New Ideas About Reaching HIV Sanctuaries in the Body A joint U.S. and Canadian team of researchers say they have confirmed how specific immune cells serve as a protected reservoir of HIV, despite potent antiretroviral (ARV) therapy. They also offer ideas for eradicating that sanctuary of cells—and the virus along with it—in a study published online June 21 in Nature Medicine.
June 19, 2009
Preterm Delivery, Low Birth Weight Unlikely with Perinatal HIV Treatment HIV treatment does not increase the risk of preterm delivery, according to a French research analysis involving more than 8,000 HIV-negative babies born to HIV-positive women over a 16-year period. The new data, published June 19 in AIDS, dispel other reports suggesting that antiretroviral (ARV) therapy, notably protease inhibitors, affects fetal development and results in low birth weight.
June 18, 2009
Interleukin-10 Blunts HIV Infection and Disease Progression People who are genetically predisposed to have high levels of a protein called interleukin-10 (IL-10), which helps regulate the immune system, may have a lower risk of becoming infected with HIV, or slower disease progression if they’re already infected with the virus, according to a study published online June 17 in The Journal of Infectious Diseases.
June 17, 2009
HIVMA Advocates for Public Insurance Option The HIV Medicine Association (HIVMA) has waded into the health care reform debate, calling for a public insurance option. HIVMA argues this will be critical to reach uninsured people living with HIV.
June 16, 2009
B Cell Test Predicts Who Will Get Meningitis A newly devised test of the immune system’s response to Cryptococcus neoformans—a fungal infection common among people with advanced HIV disease—is a strong predictor of who is most at risk for developing one of its more serious complications: a potentially lethal brain illness known as meningitis. A study published online June 15 in The Journal of Infectious Diseases documents this predictive potential and says that the test could help providers determine who would benefit most from taking antifungal drugs to prevent meningitis.
June 15, 2009
Early HIV Treatment Could Protect Against Brain Dysfunction Monkeys infected with simian immunodeficiency virus (SIV)—the primate version of HIV—were less likely to develop brain dysfunction if they were treated with antiretroviral (ARV) drugs soon after infection, according to a study published in the June 19 issue of AIDS.
June 12, 2009
Enzyme Related to Heart Disease No Higher in HIV-Positive Women Good news for HIV-positive women: They are no more likely than HIV-negative women to have elevated levels of plasma homocysteine (HCY), an enzyme associated with coronary heart disease, clogged arteries and strokes, according to a study published in the June issue of The Journal of Acquired Immune Deficiency Syndromes. The study also found that current use of antiretroviral (ARV) therapy does not appear to increase HCY levels either.
June 11, 2009
Repeat Pregnancies Likely With Only Condoms
HIV-positive women enrolled in a clinical trial testing two types of antiretroviral (ARV) therapy during pregnancy were highly likely to have a second pregnancy within two years of the first if they used only condoms as a contraceptive method, according to a study reported in a letter published in the June issue of The Journal of Acquired Immune Deficiency Syndromes.
Apricitabine Trial Continues, With Changes The experimental antiretroviral drug apricitabine (ATC) has received approval from a data safety monitoring board (DSMB) to continue with its Phase III trial beyond week 16. However, according to a Monday announcement from apricitabine’s Australia-based manufacturer Avexa, the DSMB also recommended that everyone receiving the higher dose of apricitabine continue the study on the lower dose.
June 05, 2009
New Hope for HIV Eradication Researchers may finally be on track to get at the HIV that hides inside cells and keeps the infection going; if so, they could perhaps eradicate the virus from the body entirely, according to an article published in the July issue of Retrovirology. The latest research expands on the mixed results of earlier studies of valproic acid (Depakote), an epilepsy treatment that demonstrated potential as a method of purging HIV from its cellular hiding places.
June 04, 2009
Crystal Use Might Increase Lymphoma Risk People who’ve recently used crystal methamphetamine at least once a week may be nearly four times as likely to develop non-Hodgkin’s lymphoma (NHL)—a cancer of the immune system—as people who use it less frequently or not at all, according to a study published in the July issue of Cancer Causes & Control.
June 03, 2009
Tesamorelin for Lipodystrophy Approval Application Filed Montreal-based Theratechnologies announced on Monday, June 1, that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for tesamorelin, its experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy.
June 02, 2009
Higher HIV Levels Increase Lymphoma Risk Low CD4 cells are not the only risk factor for non-Hodgkin’s lymphoma (NHL) in people living with HIV. A persistently high viral load may also up the chances of developing this potentially life-threatening cancer, according to German researchers reporting study results in the July 1 issue of The Journal of Infectious Diseases.